Literature DB >> 26733162

Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer.

Yong Chen1, Qingquan Chen2, Qicai Liu3, Feng Gao4.   

Abstract

Ovarian cancer is the most common cause of gynecological malignancy-related mortality. Human epididymis protein 4 (HE4) is a useful biomarker for ovarian cancer when either used alone or in combination with carbohydrate antigen 125 (CA125). What is more, aberrant expression of microRNA-21 (miR-21) has been shown to be involved in oncogenesis, but the relationship between miR-21 and HE4 in ovarian cancer is not clear. Tumor and adjacent tumor tissues from 43 patients with ovarian cancer were examined. Real-time polymerase chain reaction (RT-PCR) was used to detect the expression of HE4 in the carcinoma and adjacent tissues. The associations between HE4 and tumor biological characters were discussed. TaqMan(®) MicroRNA (miRNA) assays were employed to detect the expression of miR-21 in the ovarian carcinoma. In ovarian cancer, the expression of HE4 messenger RNA (mRNA) in cancer tissues was higher than adjacent tumor tissues (P < 0.0001), which was 1.299-fold of adjacent tumor tissues. And, the expression of miR-21 was also up-regulated which was significantly different in the ovarian cancer (the positive rate was 76.74 %). There was a significantly positive correlation between miR-21 and HE4 expression (r = 0.283 and P = 0.066 for HE4 mRNA, r = 0.663 and P < 0.0001 for serum HE4). There was also a significant correlation between miR-21 and tumor grade (r = 0.608, P < 0.0001). Significantly, patients with recent recurrence (less than 6 months, n = 17) have a higher miR-21 expression than those with no recent recurrence. Therefore, HE4 and miR-21 may play an important role in the development and progression of ovarian cancer and they may serve as prognostic indicators in ovarian cancer.

Entities:  

Keywords:  Human epididymis protein 4 (HE4); Immunohistochemistry; MicroRNA-21; Ovarian tumor

Mesh:

Substances:

Year:  2016        PMID: 26733162     DOI: 10.1007/s13277-015-4672-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

1.  MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein.

Authors:  Yanhui Lou; Xingsheng Yang; Fuling Wang; Zhumei Cui; Yu Huang
Journal:  Int J Mol Med       Date:  2010-12       Impact factor: 4.101

2.  The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.

Authors:  Yuji Ikeda; Kosei Hasegawa; Akira Kurosaki; Akiko Miyara; Tatsuya Hanaoka; Daisuke Shintani; Yuichi Imai; Tadaaki Nishikawa; Katsutoshi Oda; Keiichi Fujiwara
Journal:  Oncol Res Treat       Date:  2015-05-19       Impact factor: 2.825

Review 3.  HE4 in the differential diagnosis of ovarian masses.

Authors:  Teresa Granato; Maria Grazia Porpora; Flavia Longo; Antonio Angeloni; Lucia Manganaro; Emanuela Anastasi
Journal:  Clin Chim Acta       Date:  2015-04-16       Impact factor: 3.786

4.  Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer.

Authors:  Yun-Zhao Xu; Qing-Hua Xi; Wen-Liang Ge; Xiao-Qian Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2013

5.  Bead-based ELISA for validation of ovarian cancer early detection markers.

Authors:  Nathalie Scholler; Meghan Crawford; Alicia Sato; Charles W Drescher; Kathy C O'Briant; Nancy Kiviat; Garnet L Anderson; Nicole Urban
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

6.  Comprehensive analysis of HE4 expression in normal and malignant human tissues.

Authors:  Mary T Galgano; Garret M Hampton; Henry F Frierson
Journal:  Mod Pathol       Date:  2006-06       Impact factor: 7.842

Review 7.  Clinically relevant microRNAs in ovarian cancer.

Authors:  Shu Zhang; Zhen Lu; Anna K Unruh; Cristina Ivan; Keith A Baggerly; George A Calin; Zongfang Li; Robert C Bast; Xiao-Feng Le
Journal:  Mol Cancer Res       Date:  2014-10-10       Impact factor: 5.852

8.  Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.

Authors:  Tianhe Huang; Shi-Wen Jiang; Liangyi Qin; Christopher Senkowski; Christian Lyle; Karen Terry; Steven Brower; Haibin Chen; Wayne Glasgow; Yongchang Wei; Jinping Li
Journal:  Int J Mol Sci       Date:  2015-01-29       Impact factor: 5.923

9.  microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells.

Authors:  Qun Pan; Xiaoping Luo; Nasser Chegini
Journal:  Mol Hum Reprod       Date:  2009-11-11       Impact factor: 4.025

10.  Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.

Authors:  Tuulia Vallius; Johanna Hynninen; Annika Auranen; Olli Carpén; Jaakko Matomäki; Sinikka Oksa; Johanna Virtanen; Seija Grénman
Journal:  Tumour Biol       Date:  2014-09-05
View more
  5 in total

1.  The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer.

Authors:  Adam Pendlebury; Natalie J Hannan; Natalie Binder; Sally Beard; Monica Mcgauran; Peter Grant; Stephen Tong; Clare L Whitehead
Journal:  Biomed Rep       Date:  2017-01-25

2.  miR-21 Induces Chemoresistance in Ovarian Cancer Cells via Mediating the Expression and Interaction of CD44v6 and P-gp.

Authors:  Yanqing Wang; Gantao Chen; Fangfang Dai; Li Zhang; Mengqin Yuan; Dongyong Yang; Shiyi Liu; Yanxiang Cheng
Journal:  Onco Targets Ther       Date:  2021-01-12       Impact factor: 4.147

3.  The diagnostic value of serum miR-21 in patients with ovarian cancer: a systematic review and meta-analysis.

Authors:  Lili Qiu; Guangping Weng
Journal:  J Ovarian Res       Date:  2022-05-02       Impact factor: 5.506

4.  Serum MicroRNA-21 Negatively Relates to Expression of Programmed Cell Death-4 in Patients with Epithelial Ovarian Cancer

Authors:  Enas H Mahmoud; Amal Fawzy; Reham A A Elshimy
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27

5.  Defining fallopian tube-derived miRNA cancer signatures.

Authors:  Selam B Dejene; Anders W Ohman; Wei Du; Deepinder Randhawa; Anand Bradley; Niraj Yadav; Kevin M Elias; Daniela M Dinulescu; Sunita R Setlur
Journal:  Cancer Med       Date:  2019-09-10       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.